Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma
Author:
Affiliation:
1. Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK
Publisher
Future Medicine Ltd
Subject
Oncology,Immunology,Immunology and Allergy
Link
https://www.futuremedicine.com/doi/pdf/10.2217/imt.16.6
Reference16 articles.
1. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
2. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
3. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Therapeutic efficacy of plant-produced Nivolumab in transgenic C57BL/6-hPD-1 mouse implanted with MC38 colon cancer;Biotechnology Reports;2023-06
2. A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma;Cancer Immunology, Immunotherapy;2019-02-06
3. PVP‐templated novel fluorescent Ag nanomaterials synthesis and its application to bioimaging;Micro & Nano Letters;2018-06
4. Gearing up T-cell immunotherapy in cervical cancer;Current Problems in Cancer;2018-03
5. Combination of Plant Virus Nanoparticle-Based in Situ Vaccination with Chemotherapy Potentiates Antitumor Response;NANO LETT;2017
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3